Drugs / Cytarabine 2000 mg/m² qd 2 days
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03892421 | Apr 2018 → Jan 2021 | non-Hodgkin lymphoma | La Raza Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytarabine 2000 mg/m² qd 2 days | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03892421 ↗ |
| Route | Intravenous | “Cytarabine 2000 mg/m², on day 2 and 3, i.v.” NCT03892421 ↗ |